Compare CFFI & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFI | ORGO |
|---|---|---|
| Founded | 1927 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.2M | 299.8M |
| IPO Year | 1996 | 2016 |
| Metric | CFFI | ORGO |
|---|---|---|
| Price | $77.60 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 5.7K | ★ 712.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | 37.94 | ★ 1600.00 |
| EPS | ★ 2.08 | N/A |
| Revenue | $140,841,000.00 | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.27 |
| P/E Ratio | $37.02 | ★ N/A |
| Revenue Growth | 10.63 | ★ 17.04 |
| 52 Week Low | $61.45 | $2.04 |
| 52 Week High | $86.18 | $7.08 |
| Indicator | CFFI | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 53.66 |
| Support Level | $68.17 | $2.26 |
| Resistance Level | $78.93 | $2.58 |
| Average True Range (ATR) | 2.49 | 0.13 |
| MACD | -0.64 | -0.00 |
| Stochastic Oscillator | 11.82 | 70.42 |
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.